Search
Evaxion Biotech A/S
EVAXAdd to Watchlist
3.200USD
+0.100+3.23%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
26.69MMarket Cap
LossP/E TTM
More Details of Evaxion Biotech A/S Company
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Evaxion Biotech A/S Info
Ticker SymbolEVAX
Company nameEvaxion A/S
IPO dateFeb 05, 2021
CEO- -
Number of employees46
Security typeDepository Receipt
Fiscal year-endFeb 05
AddressDr. Neergaards Vej 5F
CityHOERSHOLM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryDenmark
Postal code2970
Phone
Websitehttps://evaxion.ai/
Ticker SymbolEVAX
IPO dateFeb 05, 2021
CEO- -
Company Executives of Evaxion Biotech A/S
Name
Name/Position
Position
Shareholding
Change
,
,
--
--
Name
Name/Position
Position
Shareholding
Change
,
,
--
--
FAQs
Who are the top five shareholders of Evaxion Biotech A/S?
The top five shareholders of Evaxion Biotech A/S are: ,
How many institutions hold shares of Evaxion Biotech A/S (EVAX)?
As of 2026Q1, 29 institutions hold shares of Evaxion Biotech A/S, with a combined market value of approximately 323.61K, accounting for 3.88% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 5418.00.